Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DXCM DexCom	$80.00 -1.2%	$80.08	$57.52 ▼ $117.19	$31.37B	1.46	4.34 million shs	5.24 million shs
IDXX IDEXX Laboratories	$523.92 +0.8%	$486.81	$356.14 ▼ $530.73	$42.13B	1.55	645,375 shs	1.05 million shs
MASI Masimo	$165.18 +1.5%	$159.10	$101.61 ▼ $194.88	$8.96B	1.19	639,509 shs	630,756 shs
RMD ResMed	$253.65 +1.1%	$240.71	$179.42 ▼ $263.05	$37.19B	0.78	998,267 shs	964,317 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DXCM DexCom	0.00%	-2.43%	-5.34%	+6.21%	-31.41%
IDXX IDEXX Laboratories	0.00%	+0.23%	+4.46%	+23.68%	+5.69%
MASI Masimo	0.00%	+2.47%	+10.02%	-1.45%	+25.93%
RMD ResMed	0.00%	+1.80%	+4.37%	+13.77%	+23.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DXCM DexCom	4.8308 of 5 stars	3.5	5.0	0.0	4.7	2.7	2.5	1.9
IDXX IDEXX Laboratories	3.8025 of 5 stars	1.4	5.0	0.0	3.7	3.1	2.5	1.3
MASI Masimo	4.2152 of 5 stars	3.4	1.0	0.0	4.2	2.1	3.3	1.3
RMD ResMed	4.0919 of 5 stars	2.3	1.0	3.3	4.6	2.6	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DXCM DexCom	2.95	Moderate Buy	$98.50	23.13% Upside
IDXX IDEXX Laboratories	2.78	Moderate Buy	$546.00	4.21% Upside
MASI Masimo	2.83	Moderate Buy	$191.60	15.99% Upside
RMD ResMed	2.60	Moderate Buy	$259.33	2.24% Upside

Current Analyst Ratings Breakdown

Latest MASI, RMD, IDXX, and DXCM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	DXCM DexCom	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$102.00
6/11/2025	IDXX IDEXX Laboratories	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$515.00 ➝ $580.00
5/30/2025	DXCM DexCom	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$104.00
5/22/2025	DXCM DexCom	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00 ➝ $102.00
5/20/2025	RMD ResMed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$286.00
5/19/2025	IDXX IDEXX Laboratories	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$460.00 ➝ $510.00
5/7/2025	MASI Masimo	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$193.00
5/7/2025	MASI Masimo	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$215.00 ➝ $200.00
5/7/2025	MASI Masimo	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$204.00 ➝ $185.00
5/7/2025	MASI Masimo	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$205.00 ➝ $190.00
5/5/2025	DXCM DexCom	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$90.00 ➝ $93.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DXCM DexCom	$4.03B	7.78	$2.25 per share	35.59	$5.38 per share	14.87
IDXX IDEXX Laboratories	$3.90B	10.81	$12.43 per share	42.15	$19.48 per share	26.90
MASI Masimo	$2.09B	4.28	$6.39 per share	25.86	$19.50 per share	8.47
RMD ResMed	$4.69B	7.94	$9.23 per share	27.49	$33.11 per share	7.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DXCM DexCom	$576.20M	$1.34	59.70	32.52	1.71	12.90%	30.05%	10.00%	7/24/2025 (Estimated)
IDXX IDEXX Laboratories	$887.87M	$10.82	48.42	38.58	3.83	22.76%	57.35%	26.97%	8/5/2025 (Estimated)
MASI Masimo	-$304.90M	-$9.17	N/A	35.68	N/A	-25.06%	22.56%	10.00%	8/5/2025 (Estimated)
RMD ResMed	$1.02B	$8.91	28.47	24.48	1.75	26.15%	25.67%	18.59%	7/30/2025 (Estimated)

Latest MASI, RMD, IDXX, and DXCM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	MASI Masimo	$1.24	$1.36	+$0.12	-$3.12	$367.79 million	$372.00 million
5/1/2025	Q1 2025	DXCM DexCom	$0.33	$0.32	-$0.01	$0.27	$1.02 billion	$1.04 billion
5/1/2025	Q1 2025	IDXX IDEXX Laboratories	$2.93	$2.96	+$0.03	$2.96	$998.25 million	$998.43 million
4/23/2025	Q3 2025	RMD ResMed	$2.36	$2.37	+$0.01	$2.48	$1.28 billion	$1.29 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
IDXX IDEXX Laboratories	N/A	N/A	N/A	N/A	N/A
MASI Masimo	N/A	N/A	N/A	N/A	N/A
RMD ResMed	$2.12	0.84%	N/A	23.79%	13 Years

Latest MASI, RMD, IDXX, and DXCM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/24/2025	RMD ResMed	quarterly	$0.53	0.9%	5/8/2025	5/8/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DXCM DexCom	0.55	1.50	1.32
IDXX IDEXX Laboratories	0.31	1.16	0.81
MASI Masimo	0.67	2.17	1.62
RMD ResMed	0.12	3.41	2.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DXCM DexCom	97.75%
IDXX IDEXX Laboratories	87.84%
MASI Masimo	85.96%
RMD ResMed	54.98%

Insider Ownership

Company	Insider Ownership
DXCM DexCom	0.32%
IDXX IDEXX Laboratories	0.98%
MASI Masimo	16.90%
RMD ResMed	0.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DXCM DexCom	10,300	392.11 million	390.85 million	Optionable
IDXX IDEXX Laboratories	11,000	80.42 million	79.63 million	Optionable
MASI Masimo	5,600	54.22 million	45.06 million	Optionable
RMD ResMed	9,980	146.63 million	145.59 million	Optionable

MASI, RMD, IDXX, and DXCM Headlines

Recent News About These Companies

Running Oak Capital LLC Acquires Shares of 67,844 ResMed Inc. (NYSE:RMD)

June 22 at 5:05 AM | marketbeat.com

Exchange Traded Concepts LLC Acquires 2,016 Shares of ResMed Inc. (NYSE:RMD)

June 22 at 3:21 AM | marketbeat.com

Canton Hathaway LLC Purchases Shares of 3,200 ResMed Inc. (NYSE:RMD)

June 21 at 7:09 AM | marketbeat.com

Trivant Custom Portfolio Group LLC Acquires Shares of 4,688 ResMed Inc. (NYSE:RMD)

June 19, 2025 | marketbeat.com

Janney Montgomery Scott LLC Sells 1,893 Shares of ResMed Inc. (NYSE:RMD)

June 19, 2025 | marketbeat.com

SG Americas Securities LLC Sells 14,333 Shares of ResMed Inc. (NYSE:RMD)

June 18, 2025 | marketbeat.com

ResMed Inc. (NYSE:RMD) Stake Lessened by Patton Fund Management Inc.

June 17, 2025 | marketbeat.com

QRG Capital Management Inc. Increases Stock Holdings in ResMed Inc. (NYSE:RMD)

June 17, 2025 | marketbeat.com

Ritholtz Wealth Management Buys 7,582 Shares of ResMed Inc. (NYSE:RMD)

June 17, 2025 | marketbeat.com

Assenagon Asset Management S.A. Decreases Stake in ResMed Inc. (NYSE:RMD)

June 17, 2025 | marketbeat.com

Mn Services Vermogensbeheer B.V. Sells 4,200 Shares of ResMed Inc. (NYSE:RMD)

June 16, 2025 | marketbeat.com

NorthCrest Asset Manangement LLC Purchases 1,575 Shares of ResMed Inc. (NYSE:RMD)

June 13, 2025 | marketbeat.com

ResMed Inc. (NYSE:RMD) is Birch Capital Management LLC's 5th Largest Position

June 13, 2025 | marketbeat.com

Handelsbanken Fonder AB Cuts Stock Holdings in ResMed Inc. (NYSE:RMD)

June 12, 2025 | marketbeat.com

ResMed Inc. (NYSE:RMD) CEO Sells $2,011,940.89 in Stock

June 10, 2025 | marketbeat.com

ResMed: A Mixed Bag for Investors Amid Rising Competition

June 10, 2025 | fool.com

ResMed Inc Reports Change in Beneficial Ownership

June 9, 2025 | tipranks.com

ResMed: A Sleeping Giant Hiding In Plain Sight

June 9, 2025 | seekingalpha.com

ResMed Inc. (NYSE:RMD) Shares Sold by Gateway Investment Advisers LLC

June 9, 2025 | marketbeat.com

ResMed Inc. (NYSE:RMD) Given Consensus Recommendation of "Moderate Buy" by Analysts

June 8, 2025 | marketbeat.com

ResMed Inc. (NYSE:RMD) Holdings Cut by Congress Asset Management Co.

June 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MASI, RMD, IDXX, and DXCM Company Descriptions

DexCom NASDAQ:DXCM

$80.00 -1.01 (-1.25%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$79.98 -0.02 (-0.02%)

As of 06/20/2025 07:43 PM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

IDEXX Laboratories NASDAQ:IDXX

$523.92 +4.07 (+0.78%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$524.55 +0.63 (+0.12%)

As of 06/20/2025 07:54 PM Eastern

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Masimo NASDAQ:MASI

$165.18 +2.41 (+1.48%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$165.22 +0.03 (+0.02%)

As of 06/20/2025 06:13 PM Eastern

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

ResMed NYSE:RMD

$253.65 +2.77 (+1.11%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$254.62 +0.97 (+0.38%)

As of 06/20/2025 07:54 PM Eastern

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time